Cardialen, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin a clinical trial of its MultiPulse™ Therapy (MPT™) to treat paroxysmal and persistent atrial fibrillation (AF)…
